Links for fulltext
     (May Require Subscription)
Supplementary

Article: The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (hcc)

TitleThe outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (hcc)
Authors
KeywordsAdvanced hcc
Elderly
Sorafenib
Issue Date2011
PublisherAlphaMed Press, Inc. The Journal's web site is located at http://www.theoncologist.org/
Citation
Oncologist, 2011, v. 16 n. 12, p. 1721-1728 How to Cite?
AbstractBackground. With the aging population, hepatocellular carcinoma (HCC) in the elderly represents a significant health burden. We aimed to evaluate and compare the efficacy and tolerability of single-agent sorafenib in treating elderly patients with advanced HCC versus the younger population. Methods. We retrospectively analyzed a consecutive cohort of advanced HCC patients with Child-Pugh A or B liver function and an Eastern Cooperative Oncology Group performance status score of 0-2 treated with sorafenib. The patients were categorized into older (age ≥70 years) and younger (age <70 years) groups. Treatment outcomes and related adverse events (AEs) were compared. Results. In total, 172 patients, 35 in the older (median age, 73 years) and 137 in the younger (median age, 55 years) group, were analyzed. The median progressionfree survival time was similar in the older and younger groups (2.99 months versus 3.09 months; p =.275), as was the overall survival time (5.32 months versus 5.16 months; p =.310). Grade 3 or 4 AEs were observed in 68.6% of older and 62.7% of younger patients (p=.560), with neutropenia (11.4% versus 0.7%; p =.007), malaise (11.4% versus 2.2%; p =.033), and mucositis (5.7% versus 0.0%; p =.041) being more frequently reported in the elderly cohort. Conclusions. The survival benefits and overall treatmentrelated AEs of sorafenib are comparable in elderly and younger advancedHCCpatients. Nevertheless, more vigilant monitoring in the elderly is warranted because they are more susceptible to develop neutropenia, malaise, and mucositis. ©AlphaMed Press.
Persistent Identifierhttp://hdl.handle.net/10722/144555
ISSN
2015 Impact Factor: 4.789
2015 SCImago Journal Rankings: 2.391
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Bayer Pharmaceuticals Limited
Funding Information:

Disclosures: Hilda Wong: None; Yuen Fong Tang: None; Tzy-Jyun Yao: None; Joanne Chiu: None; Roland Leung: None; Pierre Chan: None; Tan To Cheung: None; Albert C. Chan: None; Roberta W. Pang: None; Ronnie Poon: Bayer Pharmaceuticals Limited (RF); Sheung-Tat Fan: None; Thomas Yau: Bayer Schering (C/A).

References

 

DC FieldValueLanguage
dc.contributor.authorWong, Hen_HK
dc.contributor.authorTang, YFen_HK
dc.contributor.authorYao, TJen_HK
dc.contributor.authorChiu, Jen_HK
dc.contributor.authorLeung, Ren_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorCheung, TTen_HK
dc.contributor.authorChan, ACen_HK
dc.contributor.authorPang, RWen_HK
dc.contributor.authorPoon, Ren_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorYau, Ten_HK
dc.date.accessioned2012-02-03T06:13:40Z-
dc.date.available2012-02-03T06:13:40Z-
dc.date.issued2011en_HK
dc.identifier.citationOncologist, 2011, v. 16 n. 12, p. 1721-1728en_HK
dc.identifier.issn1083-7159en_HK
dc.identifier.urihttp://hdl.handle.net/10722/144555-
dc.description.abstractBackground. With the aging population, hepatocellular carcinoma (HCC) in the elderly represents a significant health burden. We aimed to evaluate and compare the efficacy and tolerability of single-agent sorafenib in treating elderly patients with advanced HCC versus the younger population. Methods. We retrospectively analyzed a consecutive cohort of advanced HCC patients with Child-Pugh A or B liver function and an Eastern Cooperative Oncology Group performance status score of 0-2 treated with sorafenib. The patients were categorized into older (age ≥70 years) and younger (age <70 years) groups. Treatment outcomes and related adverse events (AEs) were compared. Results. In total, 172 patients, 35 in the older (median age, 73 years) and 137 in the younger (median age, 55 years) group, were analyzed. The median progressionfree survival time was similar in the older and younger groups (2.99 months versus 3.09 months; p =.275), as was the overall survival time (5.32 months versus 5.16 months; p =.310). Grade 3 or 4 AEs were observed in 68.6% of older and 62.7% of younger patients (p=.560), with neutropenia (11.4% versus 0.7%; p =.007), malaise (11.4% versus 2.2%; p =.033), and mucositis (5.7% versus 0.0%; p =.041) being more frequently reported in the elderly cohort. Conclusions. The survival benefits and overall treatmentrelated AEs of sorafenib are comparable in elderly and younger advancedHCCpatients. Nevertheless, more vigilant monitoring in the elderly is warranted because they are more susceptible to develop neutropenia, malaise, and mucositis. ©AlphaMed Press.en_HK
dc.languageengen_US
dc.publisherAlphaMed Press, Inc. The Journal's web site is located at http://www.theoncologist.org/en_HK
dc.relation.ispartofOncologisten_HK
dc.subjectAdvanced hccen_HK
dc.subjectElderlyen_HK
dc.subjectSorafeniben_HK
dc.titleThe outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (hcc)en_HK
dc.typeArticleen_HK
dc.identifier.emailYao, TJ: tjyao@hkucc.hku.hken_HK
dc.identifier.emailChan, AC: acchan@hku.hken_HK
dc.identifier.emailPang, RW: robertap@hku.hken_HK
dc.identifier.emailPoon, R: poontp@hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.authorityYao, TJ=rp00284en_HK
dc.identifier.authorityChan, AC=rp00310en_HK
dc.identifier.authorityPang, RW=rp00274en_HK
dc.identifier.authorityPoon, R=rp00446en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1634/theoncologist.2011-0192en_HK
dc.identifier.pmid22135121-
dc.identifier.pmcidPMC3248771-
dc.identifier.scopuseid_2-s2.0-84855175227en_HK
dc.identifier.hkuros198345en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84855175227&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue12en_HK
dc.identifier.spage1721en_HK
dc.identifier.epage1728en_HK
dc.identifier.isiWOS:000298661000010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, H=23089414000en_HK
dc.identifier.scopusauthoridTang, YF=54879579600en_HK
dc.identifier.scopusauthoridYao, TJ=7401886444en_HK
dc.identifier.scopusauthoridChiu, J=36887309300en_HK
dc.identifier.scopusauthoridLeung, R=52364352500en_HK
dc.identifier.scopusauthoridChan, P=7403497715en_HK
dc.identifier.scopusauthoridCheung, TT=7103334165en_HK
dc.identifier.scopusauthoridChan, AC=15828849100en_HK
dc.identifier.scopusauthoridPang, RW=7004376659en_HK
dc.identifier.scopusauthoridPoon, R=7103097223en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats